Original study
Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973–1983)

https://doi.org/10.1016/0167-5273(85)90262-1Get rights and content

Abstract

We studied the evolution of chronic Chagas' disease in 107 patients with a positive Guerreiro-Machado reaction and 22 non-chagasic, non-heart disease control subjects for a follow-up period of 3 to 10 years (mean follow-up of 4.9 years). After completion of invasive and non-invasive studies, chagasic patients were classified into four groups: IA (normal ECG, without heart disease; 18 patients); IB (normal ECG, early left ventricular segmental abnormalities; 13 patients); II (abnormal ECG, advanced myocardial damage, no signs of heart failure; 42 patients); and III (abnormal ECG, end-stage, congestive heart failure; 34 patients). One out of five group IA patients re-studied with invasive methods evolved to group IB (20%); 4 group IB patients evolved to group II (33%) and 6 group II patients evolved to group III (15%). The life expectancy of patients in groups IA and IB (normal ECG) was similar to that of our control group, whereas in groups II and III it was significantly decreased (P < 0.001). Nine group II patients (23%) and 28 group III patients (82%) died during the follow-up period. Main terminal events were refractory congestive heart failure, sudden death and systemic thromboembolism.

Our findings suggest that chronic Chagas' disease follows an evolutionary course from asymptomatic, normal ECG group I stage to arrhythmic (II) and congestive (III) stages. Subjects with a positive Guerreiro-Machado reaction showed a significantly lower life expectancy than our control group, but only when clinical and/or ECG abnormalities were identified.

References (40)

  • C Chagas

    Nova entidad morbida do homen: resumo general dos estudos etiologicos e clinocos

    Mem Inst Oswaldo Cruz

    (1911)
  • FS Laranja et al.

    Chagas' disease. A clinical, epidemiologic and pathologic study

    Circulation

    (1956)
  • K Kloetzel et al.

    Mortality in Chagas' disease: life-table for the period 1949–1967 in an unselected population

    Rev Inst Méd Trop São Paulo

    (1969)
  • JJ Puigbó et al.

    Cuatro años de estudio longitudinal de una comunidad rural con endemicidad chagásica

    Bol Of Sanit Panam

    (1969)
  • F Moleiro et al.

    La dinámica epidemiológica de la enfermedad de Chagas en El Valle de los Naranjos. Estado Carabobo-Venezuela

    Arch Ven Med Trop Parasitol Med

    (1973)
  • M Mijares

    Contribución al estudio de la patología de la miocarditis chagásica en Venezuela

    Arch Hosp Vargas

    (1965)
  • HA Carrasco et al.

    Aspectos clínicos de la enfermedad de Chagas: diagnóstico de daño miocardico

    Interciencia

    (1983)
  • M Medina et al.

    Diagnóstico por métodos no invasivos de daño ventricular izquierdo incipiente en pacientes chagásicos. Utilidad de la ecocardiografía y la fonomecanocardiografía

    Arch Inst Cardiol Mex

    (1980)
  • A Molina et al.

    La prueba de esfuerzo en la miocardiopatía chagásica crónica. Su valor en el diagnóstico precoz

    Arq Bras Cardiol

    (1981)
  • HA Carrasco et al.

    Estudio de la función del nodo sinusal y de la conducción atrioventricular en pacientes con enfermedad de Chagas

    Arch Inst Cardiol Mex

    (1982)
  • Cited by (96)

    • Trypanosomiasis

      2022, Greene's Infectious Diseases of the Dog and Cat, Fifth Edition
    • The role of CCR5 in Chagas disease - a systematic review

      2016, Infection, Genetics and Evolution
    • Global economic burden of Chagas disease: A computational simulation model

      2013, The Lancet Infectious Diseases
      Citation Excerpt :

      Estimates generated by the model were much the same as those currently in the scientific literature in many ways. When individuals who entered the model were assumed to be 30 years of age (similar to 37·5 years [SD 13] reported by Espinosa and colleagues22 as the average age of those with indeterminate disease), onset of cardiomyopathy occurred at 52 years (11) and congestive heart failure at 60 years (12), which is much the same as the 52 years (14) for cardiomyopathy and 55 years (11) for congestive heart failure identified by Espinosa and colleagues and in an additional study in which the age of patients with cardiomyopathy ranged from 49 to 85 years.23 In our model, average duration of disease for those with cardiomyopathy was 11·6 years (10) and for those with congestive heart failure was 13·2 years (7·5), which is shorter than some other estimates (eg, 20–30 years for cardiomyopathy and 10–20 years for congestive heart failure23).

    View all citing articles on Scopus

    Supported by grant No M-226 from the “Consejo de Desarrollo Científico y Humanistico de la Universidad de Los Andes”, Mérida, Venezuela.

    View full text